Stoke Therapeutics, Inc.

Historical 13F Holders

Symbol
STOK
CUSIP
86150R107
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 86150R107 since 12/18/2024, largest first.

Filer % of Class Filed
RTW Investments, LP 13G/A
9.9% 5/15/2026
Event 3/31/2026
FMR LLC 13G/A
8.5% 8/6/2026
Event 6/30/2026
BlackRock, Inc. 13G/A 6.8% 10/17/2025
Event 9/30/2025
Redmile Group, LLC 13G/A
6.7% 5/15/2026
Event 3/31/2026
Lynx1 Capital Management LP 13G/A
6.5% 8/14/2026
Event 6/30/2026
Morgan Stanley 13G/A
6.5% 2/3/2025
Event 12/31/2024
Baker Bros. Advisors LP 13G/A
5.8% 2/17/2026
Event 12/31/2025
Biotechnology Value Fund L P 13G
5.6% 9/30/2026
Event 9/23/2026
Wellington Management Group LLP 13G
5.2% 5/15/2026
Event 3/31/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (5)
Toronto Dominion Bank 13G/A
4.9% 8/12/2026
Event 6/30/2026
BlackRock Portfolio Management LLC 13G/A 4.7% 7/15/2025
Event 6/30/2025
Skorpios Trust 13D/A
4.1% 8/26/2025
Event 8/22/2025
Cowen Financial Products LLC 13G/A 0% 11/14/2025
Event 9/30/2025
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 3 2.84 k $73.8 k
2026 Q2 203 79.0 M $2.58 B
2026 Q1 207 71.1 M $2.31 B
2025 Q4 193 67.0 M $2.13 B
2025 Q3 159 67.7 M $1.57 B
2025 Q2 138 68.9 M $782 M
2025 Q1 130 63.4 M $422 M
2024 Q4 135 58.3 M $643 M
2024 Q3 126 58.6 M $720 M
2024 Q2 124 66.1 M $893 M
2024 Q1 117 62.5 M $843 M
2023 Q4 89 50.0 M $263 M
2023 Q3 104 44.0 M $173 M
2023 Q2 107 46.5 M $495 M
2023 Q1 100 44.6 M $372 M
2022 Q4 111 40.7 M $376 M
2022 Q3 108 42.3 M $544 M
2022 Q2 96 43.1 M $569 M
2022 Q1 103 41.4 M $871 M
2021 Q4 98 35.5 M $856 M
2021 Q3 92 19.4 M $492 M
2021 Q2 102 20.9 M $703 M
2021 Q1 114 39.1 M $1.52 B
2020 Q4 103 38.7 M $2.40 B
2020 Q3 93 34.6 M $1.16 B
2020 Q2 72 34.9 M $825 M
2020 Q1 69 34.8 M $796 M
2019 Q4 66 33.6 M $952 M
2019 Q3 56 16.1 M $341 M
2019 Q2 49 14.3 M $410 M